[Cl:1][C:2]1[CH:3]=[C:4]2[NH:11][CH2:10][CH2:9][N:5]2[C:6](=[O:8])[N:7]=1.[CH:12]1(B(O)O)[CH2:14][CH2:13]1.N1C=CC(C2C=CN=CC=2)=CC=1.C([O-])([O-])=O.[Na+].[Na+]>ClCCCl.C([O-])(=O)C.[Cu+]>[Cl:1][C:2]1[CH:3]=[C:4]2[N:11]([CH:12]3[CH2:14][CH2:13]3)[CH2:10][CH2:9][N:5]2[C:6](=[O:8])[N:7]=1
A mixture of 7-chloro-2,3-dihydroimidazo[1,2-c]pyrimidin-5(1H)-one (300 mg, 1.75 mmol), cyclopropylboronic acid (300 mg, 3.50 mmol), 4,4′-bipyridine (273 mg, 1.75 mmol), copper (I) acetate (214 mg, 1.75 mmol) and Na2CO3 (371 mg, 3.50 mmol) in 1,2-dichloroethane (DCE) (20 mL) was stirred at 70° C. for 3 h and concentrated to remove solvent under vacuo. Purification via Biotage system with inverse phase column (water and acetonitrile as eluent) afforded the title product (200 mg).
読み込み中…
